Inovio Pharmaceuticals, Inc. (INO) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2023
Loading P/E history...
INO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Inovio Pharmaceuticals, Inc. (INO) trades at a price-to-earnings ratio of -0.8x, with a stock price of $1.37 and trailing twelve-month earnings per share of $-181.17.
The current P/E is 1645% below its 5-year average of 0.0x. Over the past five years, INO's P/E has ranged from a low of 0.0x to a high of 0.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, INO trades at a 103% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, INO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our INO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
INO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 3.6Lowest | - | +307% | |
| $2B | 77.5 | - | +503% | |
| $178M | 10.6 | - | +150% | |
| $166B | 19.8 | 0.15Best | +1684%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
INO Historical P/E Data (2023–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $6.12 | $132.69 | 0.0x | -6% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $4.68 | $131.37 | 0.0x | -27% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $5.40 | $132.73 | 0.0x | -17% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $9.84 | $133.86 | 0.1x | +50% |
Average P/E for displayed period: 0.0x
See INO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINO — Frequently Asked Questions
Quick answers to the most common questions about buying INO stock.
Is INO stock overvalued or undervalued?
INO current P/E: -0.8x. 5-year average P/E: 0.0x. Percentile: N/A.
How does INO's valuation compare to peers?
Inovio Pharmaceuticals, Inc. P/E of -0.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is INO's PEG ratio?
INO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2023.